<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076747/results/search/test_trace/results.xml">
  <result pre="that the work is properly cited. For commercial re-use, please" exact="contact" post="journals.permissions@oup.comciz370.pdf adoptive T cell therapy cytomegalovirus stem cell transplantation"/>
  <result pre="no effective therapy was yet available [1]. Today, with adequate" exact="screening" post="tools and effective, albeit toxic, antiviral drugs at our"/>
  <result pre="safe and lowered the risk of late or persistent CMV" exact="infection" post="compared to a high-risk control group. However, CMV infection"/>
  <result pre="CMV infection compared to a high-risk control group. However, CMV" exact="infection" post="in the setting of stem cell transplantation is a"/>
  <result pre="serostatus is an important determinant of the risk of CMV" exact="infection" post="after allogeneic HSCT. Leaving apart D–/R– recipients, the risk"/>
  <result pre="donor-derived ATC, although they have the highest risk of CMV" exact="infection" post="and disease [8]. The risk is high because the"/>
  <result pre="CMV-positive adults. Some haploidentical transplant protocols use nondepleted grafts and" exact="treatment" post="of the recipient with, for example, antithymocyte globulin, as"/>
  <result pre="failure of ATC in certain donor/recipient pairs. GRAFT-VERSUS-HOST DISEASE CMV" exact="infection" post="and GVHD are intricately related [11]. In all previous"/>
  <result pre="Rev2014; 258:12–29.24517423 3.MaffiniE, GiacconeL, FestucciaM, BrunelloL, BuscaA, BrunoBTreatment of CMV" exact="infection" post="after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol2016;"/>
  <result pre="al.First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV" exact="infection" post="by promoting antiviral immunity after allogenic stem cell transplantation."/>
  <result pre="transplantation. Clin Infect Dis2020; 70:1429–37. 7.CamargoJF, KomanduriKVEmerging concepts in cytomegalovirus" exact="infection" post="following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell"/>
  <result pre="et al.CMV seronegative donors: effect on clinical severity of CMV" exact="infection" post="and reconstitution of CMV-specific immunity. Transpl Immunol2018; 49:54–8.29679650 9.HanleyPJ,"/>
  <result pre="RuferN, et al.Infusion of cytomegalovirus (CMV)-specific T cells for the" exact="treatment" post="of CMV infection not responding to antiviral chemotherapy. Blood2002;"/>
  <result pre="of cytomegalovirus (CMV)-specific T cells for the treatment of CMV" exact="infection" post="not responding to antiviral chemotherapy. Blood2002; 99:3916–22.12010789 15.FeuchtingerT, OpherkK,"/>
  <result pre="BethgeWA, et al.Adoptive transfer of pp65-specific T cells for the" exact="treatment" post="of chemorefractory cytomegalovirus disease or reactivation after haploidentical and"/>
  <result pre="18.PeggsKS, VerfuerthS, PizzeyA, et al.Adoptive cellular therapy for early cytomegalovirus" exact="infection" post="after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet2003;"/>
 </snippets>
</snippetsTree>
